Focused on interventions for heart failure, this session presents data on mitral regurgitation post-alcohol septal ablation, outcomes from high-risk PCI supported by Impella CP, evolving trends in ECMO utilization for cardiogenic shock, and six-month patient outcomes guided by shock team management strategies.

This session showcases exemplary cases in stable coronary artery disease, emphasizing complex diagnostic and therapeutic challenges such as ambiguous angiographic findings, refractory vasospastic angina, catastrophic no-reflow phenomena, and the application of physiology-guided PCI and coronary sinus reducers.

This session explores the evolving role of nurses and allied professionals in interventional cardiology, addressing challenges in role definitions, collaborative responsibilities with physicians, and strategies for professional recognition and safety enhancement within the cath lab environment.

Focused on the complexities of redo transcatheter aortic valve implantation (TAVI), this session covers innovative techniques such as jailed-balloon to prevent sinus sequestration, CT-guided emergency valve-in-valve procedures, alternative access routes, and strategies to manage coronary occlusion risks during multiple valve interventions.

Previous clinical trials suggested that ultra-thin strut biodegradable polymer sirolimus-eluting stent (BP-SES) may be associated with lower target lesion failure (TLF) when compared to durable polymer everolimus-eluting stents (DP-EES). However, the possible underlying mechanisms remain unclear. Therefore, the all-comers CASTLE study was designed to assess the...

Alex Sticchi provides his take on the results of the RIVER trial, which were presented by Pedro Gabriel Barros E Silva during the ESC 2023 congress in Amsterdam.

Rivaroxaban versus Warfarin in Patients with Bioprosthetic Valves According to Valvular Heart Disease Etiology, and Thrombotic and Bleeding Risks: Insights from...

Nicola Ryan reports on the BIOFLOW DAPT trial results presented during the ESC 2023 Congress in Amsterdam by Marco Valgimigli and published in Circulation.

BIOFLOW-DAPT is an open-label randomised trial comparing the safety and efficacy of a biodegradable-polymer sirolimus-eluting stent with a durable-polymer zotarolimus-eluting stent in high-bleeding risk patients...